Inovio Biomedical's Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials.

Interim Data from First-in-Man Studies to Be Reported at DNA Vaccines 2007 Conference

SAN DIEGO -- Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA-based vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today that partners of the company will present new interim data from two phase I clinical trials of plasmid-based immunotherapies using Inovio's electroporation delivery technology at the Third International Conference on DNA Vaccines in Malaga, Spain, being held May 23-25, 2007 at the Torrequebrada Hotel. Dr. Christian Ottensmeier of the University of Southampton will present data relating to a prostate cancer vaccine. Dr. Richard Heller of the University of South Florida and Moffitt Cancer Center will present data on a melanoma immunotherapy study. These clinical studies are assessing safety, tolerability and immune responses of these products in conjunction with Inovio's electroporation-based DNA delivery technologies, which are designed to enhance the potency of immunotherapies including DNA vaccines.

In addition, Dr. Iacob Mathiesen of Inovio will present a general overview of electroporation delivery of immunotherapy products currently in clinical trials; Dr. Alain Rolland of Vical, Inc. will present preclinical data of a DNA vaccine for human cytomegalovirus (CMV) delivered with Inovio technology; Dr. Connie Schmaljohn of USAMRIID at Fort Detrick, MD, will present preclinical data from electroporated DNA vaccines for key biodefense targets; and Dr. Michael Eagan of Wyeth Research will present non-human primate data of an HIV vaccine currently in development with Inovio.

"Inovio has been fortunate to have collaborations with, in our opinion, some of the best scientists in the world to work with us on the development of multiple immunotherapy products delivered using our proprietary electroporation technology," stated Avtar Dhillon, MD, Inovio's CEO. "We look forward to the presentation of this data by our academic, governmental and industrial partners at this important international meeting."

About Inovio's Immunotherapy Products

DNA-based immunotherapy products have the potential to by-pass inherent scientific obstacles of conventional vaccines that prevent their development for cancer and chronic infectious diseases such as HIV and hepatitis C. Pre-clinical data has indicated the potential ability of Inovio's technologies to safely and effectively deliver and significantly enhance the potency of such immunotherapies.

Inovio's DNA-based immunotherapy products consist of DNA plasmids and the Elgen and MedPulser DNA delivery systems. DNA plasmids are designed to express antigens that can induce an immune response specific to a cancer or infectious disease-causing organism. These plasmids are created synthetically and readily manufactured using well-established bacterial fermentation and purification technology. After a plasmid is delivered into muscle or tumor cells, production of the desired antigens may then induce a preventive or therapeutic immune response against the targeted disease. Inovio's advanced electroporation devices facilitate delivery and expression of such immunotherapies and have been shown in primate studies to boost the immune response by orders of magnitude over DNA plasmid alone. Breast cancer, prostate cancer, melanoma, HIV and hepatitis C virus are among the current targets of therapies employing Inovio technology.

Inovio is poised to deliver advanced DNA-based immunotherapies, devices and know-how in this rapidly advancing field. The company is actively licensing its technology to pharmaceutical and biotechnology companies and supporting early stage clinical studies arising from its own research efforts or through academic collaborations.

About Inovio Biomedical Corporation

Inovio Biomedical (AMEX: INO) is focused on commercializing its Selective Electrochemical Tumor Ablation (SECTA) therapy and development of multiple DNA-based immunotherapies using its delivery platform for gene-based treatments. SECTA is a local ablation therapy for solid tumors designed to selectively kill cancerous cells and minimize cosmetic or functional impacts to predominantly healthy tissue typically treated around a tumor. Inovio is moving its lead product, the MedPulser[R], through pre-marketing studies for head & neck and skin cancers in Europe, where it has CE Mark accreditation, a U.S. Phase III pivotal study for head and neck cancer, and a Phase I/II trial for breast cancer. Inovio's DNA delivery partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, and the U.S. Army, with four DNA-based immunotherapies in Phase I clinical studies. Inovio is a leader in developing human therapeutic applications of electroporation, which uses brief, controlled electrical pulses to increase both cellular uptake of a useful biopharmaceutical and, in the case of gene-based treatments, levels of gene expression. Inovio's technology is protected by an extensive patent portfolio covering in vivo electroporation. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our plans to develop our electroporation drug and gene delivery technology. Actual events or results may differ from our expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that pre-clinical results referenced in this release may not be indicative of results achievable from testing in humans), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of Inovio's technology as a delivery mechanism, the availability or potential availability of alternative therapies or treatments for the conditions targeted by Inovio or its collaborators , including alternatives that may be more efficacious or cost-effective than any therapy or treatment that Inovio and its collaborators hope to develop, evaluation of potential opportunities, issues involving patents and whether they or licenses to them will provide Inovio with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether Inovio can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2006, our 10-Q for the three months ending March 31, 2007, and other regulatory filings. There can be no assurance that any product in our product pipeline will be successfully developed or manufactured, or that final results of clinical studies will be supportive of regulatory approvals required to market licensed products.